Adalimumab/etanercept/infliximab

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1432卷 / 1期
关键词：
D O I：
10.1007/s40278-012-0154-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [41] Comparison of Efficiency and Adverse Effects of Etanercept, Infliximab and Adalimumab in Patients with Psoriasis Vulgaris
    Sen, Ayse Pekdemir
    Onsun, Nahide
    Su, Ozlem
    Cinkaya, Ayse
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2012, 46 (01): : 11 - 14
  • [42] JUDICIARY BRANCH IN BRAZILAN ANALYSIS OF JUDICIAL DECISIONS INVOLVING ETANERCEPT, INFLIXIMAB AND ADALIMUMAB
    Patterson, I
    VALUE IN HEALTH, 2014, 17 (03) : A235 - A235
  • [43] Adalimumab, Etanercept, and Infliximab modify the oxidant/antioxidant status in patients with chronic arthritides
    Coaccioli, S.
    Biondi, R.
    Puxeddu, A.
    CLINICA TERAPEUTICA, 2009, 160 (03): : 181 - 181
  • [44] A difference in effectiveness between infliximab, etanercept and adalimumab in patients with rheumatoid arthritis.
    Kievit, Wietske
    Fransen, Jaap
    Kuper, Ina H.
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    De Rooij, Dirk jan R. A. M.
    de Gendt, Carla M.
    Ronday, Karel H.
    Brus, Herman L. M.
    van Ooijen, Piet C. M.
    van Riel, Piet C. L. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S309 - S310
  • [45] Adalimumab/etanercept
    Reactions Weekly, 2012, 1432 (1) : 6 - 6
  • [46] Drug-survival, effectiveness and safety of infliximab, adalimumab and etanercept in rheumatoid arthritis patients
    Flendrie, M.
    Creemers, M. C. W.
    Welsing, P. M. J.
    Van den Hoogen, F. H. J.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 191 - 191
  • [47] COMPARISON OF ANTERIOR UVEITIS OCCURRENCE DURING TREATMENT WITH SECUKINUMAB, ADALIMUMAB, INFLIXIMAB AND ETANERCEPT IN SPONDYLOARTHRITIS
    Lindstrom, U.
    Bengtsson, K.
    Olofsson, T.
    Di Giuseppe, D.
    Glintborg, B.
    Forsblad-D'elia, H.
    Jacobsson, L. T. H.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 9 - 10
  • [48] Plasma Cytokines for the Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis
    Karamova, Arfenya
    Znamenskaya, Ludmila
    Vorontsova, Anastasiia
    Obraztsova, Olga
    Nikonorov, Alexandr
    Nikonorova, Eugenia
    Deryabin, Dmitry
    Kubanov, Alexey
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
  • [49] Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
    Bonafede, Machaon
    Watson, Crystal
    Joseph, George
    Princic, Nicole
    Harrison, David J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S778 - S778
  • [50] Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample
    Yeaw, Jason
    Watson, Crystal
    Fox, Kathleen M.
    Schabert, Vernon F.
    Goodman, Seth
    Gandra, Shravanthi R.
    ADVANCES IN THERAPY, 2014, 31 (04) : 410 - 425
12345